Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Camara, Rafael J. A.; Schwentner, Lukas; Friedl, Thomas W. P. et al.
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trialBREAST CANCER RESEARCH AND TREATMENT. Bd. 175. H. 3. 2019 S. 627-635
Hechtner, Marlene; Eichler, Martin; Wehler, Beatrice et al.
Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional StudyJOURNAL OF THORACIC ONCOLOGY. Bd. 14. H. 3. 2019 S. 420-435
Cortes, Jorge E.; Khaled, Samer; Martinelli, Giovanni et al.
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trialLANCET ONCOLOGY. Bd. 20. H. 7. 2019 S. 984-997
Finn, Richard S.; Kudo, Masatoshi; Kang, Yoon-Koo et al.
Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 37. H. 4. 2019
Llovet, Josep M.; Yen, Chia-Jui; Finn, Richard S. et al.
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).JOURNAL OF CLINICAL ONCOLOGY. Bd. 37. H. 15. 2019
Zhu, Andrew X.; Kang, Yoon-Koo; Yen, Chia-Jui et al.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY. Bd. 20. H. 2. 2019 S. 282-296
Zhu, Andrew X.; Finn, Richard S.; Galle, Peter R. et al.
Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoproteinLANCET ONCOLOGY. Bd. 20. H. 4. 2019 S. E191-E191
Salwender, Hans; Bertsch, Uta; Weisel, Katja et al.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaBMC CANCER. Bd. 19. 2019
Wollschlaeger, Daniel; Blettner, Maria; Pokora, Roman
Re: "Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands"JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. Bd. 111. H. 9. 2019 S. 1000-1001
Schattenberg, Joern M.; Loomba, Rohit
Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced FibrosisHEPATOLOGY. Bd. 69. H. 3. 2019 S. 934-936